Who
Diane L. Parks
Director
Company insider
Files Form 4 as: Director, Soligenix; Director, Kura Oncology; Director, Celularity; Director, Cti Biopharma.
In numbers
- Trades disclosed
- 48
- Buys
- 1
- Sells
- 0
- Bought
- $14K
- Sold
- $0
- Companies
- 4
- Companies where not an officer
- 4
- First trade
- 8 Jul 2019
- Last trade
- 12 Oct 2026
- Last filed
- 13 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Oct 2026filed 13 Oct 2026 | SNGX Soligenixoption or derivative · Biotechnology | SEC FORM 4 Code D | —6 at $0.00 | filing |
| 12 Oct 2026filed 13 Oct 2026 | SNGX Soligenixoption or derivative · Biotechnology | SEC FORM 4 Code D | —128 at $0.00 | filing |
| 12 Oct 2026filed 13 Oct 2026 | SNGX Soligenixoption or derivative · Biotechnology | SEC FORM 4 Code D | —56 at $0.00 | filing |
| 12 Oct 2026filed 13 Oct 2026 | SNGX Soligenixoption or derivative · Biotechnology | SEC FORM 4 Code D | —63 at $0.00 | filing |
| 12 Oct 2026filed 13 Oct 2026 | SNGX Soligenixoption or derivative · Biotechnology | SEC FORM 4 Code D | —121 at $0.00 | filing |
| 12 Oct 2026filed 13 Oct 2026 | SNGX Soligenixoption or derivative · Biotechnology | SEC FORM 4 Code D | —192 at $0.00 | filing |
| 17 Sep 2026filed 18 Sep 2026 | SNGX Soligenixoption or derivative · Biotechnology | SEC FORM 4 Code A | —78,947 at $0.00 | filing |
| 17 Sep 2026filed 18 Sep 2026 | SNGX Soligenixoption or derivative · Biotechnology | SEC FORM 4 Code A | —78,947 at $0.00 | filing |
| 4 Jun 2026filed 4 Jun 2026 | KURA Kura Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 4 Jun 2026filed 4 Jun 2026 | KURA Kura Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 12 Jan 2026filed 15 Jan 2026 | CELU CelularityBiotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 12 Jan 2026filed 15 Jan 2026 | CELU CelularityBiotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 12 Jan 2026filed 14 Jan 2026 | CELU CelularityBiotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 12 Jan 2026filed 14 Jan 2026 | CELU CelularityBiotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 29 Dec 2025filed 30 Dec 2025 | CELU Celularityoption or derivative · Biotechnology | SEC FORM 4 Code A | —156,250 at $0.00 | filing |
| 29 Dec 2025filed 30 Dec 2025 | CELU CelularityBiotechnology | SEC FORM 4 Code A | —125,000 at $0.00 | filing |
| 19 Dec 2025filed 22 Dec 2025 | CELU CelularityBiotechnology | SEC FORM 4 Code A | —67,416 at $0.00 | filing |
| 19 Nov 2025filed 21 Nov 2025 | CELU CelularityBiotechnology | SEC FORM 4 Code A | —61,539 at $0.00 | filing |
| 20 Jun 2025filed 20 Jun 2025 | SNGX Soligenixoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,647 at $0.00 | filing |
| 5 Jun 2025filed 6 Jun 2025 | KURA Kura Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —28,500 at $0.00 | filing |
News
Reviewing Soligenix (NASDAQ:SNGX) and Curis (NASDAQ:CRIS)SNGX · themarketsdaily.com · 17 Oct 2026
0 headlines in the last 90 days name Diane L. Parks; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.